Freedom of Information
- Title
- Prescribing: dermatology and respiratory
- Reference Number
- RF23-438
- Request Details
Q1. How many patients were treated in June 2023 (or latest available month) by the Dermatology department with the following drugs:
• Abrocitinib (Cibinqo)
• Baricitinib (Olumiant)
• Dupilumab (Dupixent)
• Omalizumab (Xolair)
• Tralokinumab (Adtralza)
• Upadacitinib (Rinvoq)Q2. How many patients were treated in June 2023 (or latest available month) by the Respiratory Medicine departments with the following drugs:
• Benralizumab (Fasenra)
• Dupilumab (Dupixent)
• Mepolizumab (Nucala)
• Omalizumab (Xolair)
• Reslizumab (Cinqaero)
• Tezepelumab (Tezspire)
- Response
-
- rf23-438-response.pdf
- Date of Disclosure
- 31/07/2023